Competitive Pressure And Lower Demand Will Likely Weigh On Merck's Anti-Infective Drug Portfolio |
| May 23, 2018 | May 2018 Bond Updates |
|
Merck’s (NYSE: MRK) Anti-Infective drugs account for over 25% of the company’s value, according to our estimates. This can be attributed to a large portfolio of around a dozen drugs within this segment. The key drugs are Isentress, Gardasil, Proquad, and Zepatier, which together account for 60% of.. |
| View more at: https://www.forbes.com/sites/greatspeculations/2018/05/22/competitive-pressure-and-lower-demand-will-likely-weigh-on-mercks-anti-infective-drug-portfolio/?ss=markets |
| Related News |
|